Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic

Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene
              Laherparepvec In Patients With Metastatic Melanoma

PR Newswire

THOUSAND OAKS, Calif., Nov. 18, 2013

THOUSAND OAKS, Calif., Nov. 18, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today
announced interim overall survival (OS) results from a pivotal Phase 3 trial
evaluating talimogene laherparepvec in patients with unresected stage IIIB,
IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating
factor (GM-CSF). Results will be presented today during an oral session at the
2013 Society for Melanoma Research (SMR) Congress, in Philadelphia. 

At a predefined interim analysis of this Phase 3 study, median OS was 23.3
months in the talimogene laherparepvec arm over 19.0 months in the GM-CSF arm
(HR = 0.79, 95 percent CI 0.61-1.02; p=0.0746). Differences in survival rates
were pronounced in the subset of patients with stage IIIB, IIIC or IV M1a
disease (HR = 0.56, 95 percent CI, 0.38-0.81) or who received talimogene
laherparepvec asfirst-line treatment (HR = 0.49, 95 percent CI, 0.33-0.74),
each comprising approximately 50 percent of the study population.

"The interim overall survival subset results complement the durable response
data we reported earlier this year and these endpoints appear to correlate
with each other in terms of where the most benefit is being seen in this
trial," said Sean E. Harper, M.D., executive vice president of Research and
Development at Amgen. "We look forward to the mature overall survival data
expected in the first half of next year."

The most frequently observed adverse events were fatigue, chills and pyrexia.
The most common serious adverse events include disease progression in both
arms, and cellulitis and pyrexia in the talimogene laherparepvec arm. Serious
adverse events occurred in 26 percent of talimogene laherparepvec patients and
13 percent of GM-CSF patients. Immune-mediated events were reported

"A favorable trend in overall survival was observed in patients who received
talimogene laherparepvec and the trend was pronounced in patients with stage
III and IV M1a disease where an important clinical need exists for patients
whose disease has not yet spread to distant organs," said Howard Kaufman,
M.D., professor and director of the section of surgical oncology in the
Department of General Surgery, Rush University Medical Center in Chicago. "I
look forward to seeing the final results next year."

Trial Design
This trial was a global, randomized, open-label, Phase 3 trial to evaluate the
safety and efficacy of talimogene laherparepvec compared to a control therapy
with GM-CSF in over 400 patients with unresected stage IIIB, IIIC or IV

Patients were randomized 2:1 to receive either talimogene laherparepvec
intralesionally every two weeks or GM-CSF subcutaneously for the first 14days
of each 28 day cycle. Treatment could last for up to 18 months. Where
appropriate, stable or responding patients could receive additional treatment
on an extension protocol.

About Melanoma
Melanoma is a type of skin cancer that is characterized by the uncontrolled
growth of melanocytes, which are the cells responsible for providing pigment
to the skin.^1 Melanoma is the most aggressive and serious form of skin cancer
in which the best treatment approach involves early detection.^2 Because it is
not always possible to detect cancer in its earlier stage, it can sometimes
spread, or metastasize,to other parts of the body.^3 The prevalence of
metastatic melanoma patients facing recurrence from an earlier stage of
disease is predicted to increase by 43 percent by 2015.^4 Metastatic melanoma
remains a devastating and difficult-to-treat disease with a high unmet need.

Currently, 132,000 melanoma cases occur globally each year.^5 In the United
States (U.S.), while melanoma accounts for less than five percent of skin
cancer cases, it causes the most skin cancer deaths.^5 The number of new cases
of melanoma in the U.S. has been increasing for the last 30 years.^5

About Talimogene Laherparepvec
Talimogene laherparepvec is an investigational oncolytic immunotherapy
designed to selectively replicate in tumor tissue and to initiate a systemic
anti-tumor immune response. Talimogene laherparepvec is injected directly into
tumor tissue and is intended to replicate preferentially in tumor cells
causing lytic cell death and releasing an array of tumor specific antigens.
Talimogene laherparepvec is also engineered to express GM-CSF, a white blood
cell growth factor that can help to activate the immune system. The aim of
this combination of actions is to induce a systemic anti-tumor immune response
that targets tumor cells throughout the body.

About Amgen
Amgen is committed to unlocking the potential of biology for patients
suffering from serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics
manufacturing expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer since 1980,
Amgen has grown to be the world's largest independent biotechnology company,
has reached millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.

For more information, visit and follow us on

Forward-Looking Statements
This news release contains forward-looking statements that are based on
management's current expectations and beliefs and are subject to a number of
risks, uncertainties and assumptions that could cause actual results to differ
materially from those described. All statements, other than statements of
historical fact, are statements that could be deemed forward-looking
statements, including estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and
prescriber patterns or practices, reimbursement activities and outcomes and
other such estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed below and more
fully described in the Securities and Exchange Commission(SEC) reports filed
byAmgen, includingAmgen'smost recent annual report on Form 10-K and any
subsequent periodic reports on Form 10-Q and Form 8-K.Please refer to
Amgen'smost recent Forms 10-K, 10-Q and 8-K for additional information on the
uncertainties and risk factors related to our business.Unless otherwise
noted,Amgenis providing this information as ofNov. 18, 2013, and expressly
disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ
materially from those we project. Discovery or identification of new product
candidates or development of new indications for existing products cannot be
guaranteed and movement from concept to product is uncertain; consequently,
there can be no guarantee that any particular product candidate or development
of a new indication for an existing product will be successful and become a
commercial product.Further, preclinical results do not guarantee safe and
effective performance of product candidates in humans.The complexity of the
human body cannot be perfectly, or sometimes, even adequately modeled by
computer or cell culture systems or animal models. The length of time that it
takes for us to complete clinical trials and obtain regulatory approval for
product marketing has in the past varied and we expect similar variability in
the future. We develop product candidates internally and through licensing
collaborations, partnerships and joint ventures. Product candidates that are
derived from relationships may be subject to disputes between the parties or
may prove to be not as effective or as safe as we may have believed at the
time of entering into such relationship. Also, we or others could identify
safety, side effects or manufacturing problems with our products after they
are on the market.Our business may be impacted by government investigations,
litigation and product liability claims. If we fail to meet the compliance
obligations in the corporate integrity agreement between us and the U.S.
government, we could become subject to significant sanctions.We depend on
third parties for a significant portion of our manufacturing capacity for the
supply of certain of our current and future products and limits on supply may
constrain sales of certain of our current products and product candidate

In addition, sales of our products are affected by the reimbursement policies
imposed by third-party payers, including governments, private insurance plans
and managed care providers and may be affected by regulatory, clinical and
guideline developments and domestic and international trends toward managed
care and healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement.Government and others' regulations
and reimbursement policies may affect the development, usage and pricing of
our products.In addition, we compete with other companies with respect to
some of our marketed products as well as for the discovery and development of
new products. We believe that some of our newer products, product candidates
or new indications for existing products, may face competition when and as
they are approved and marketed. Our products may compete against products that
have lower prices, established reimbursement, superior performance, are easier
to administer, or that are otherwise competitive with our products. In
addition, while we routinely obtain patents for our products and technology,
the protection offered by our patents and patent applications may be
challenged, invalidated or circumvented by our competitors and there can be no
guarantee of our ability to obtain or maintain patent protection for our
products or product candidates. We cannot guarantee that we will be able to
produce commercially successful products or maintain the commercial success of
our existing products.Our stock price may be affected by actual or perceived
market opportunity, competitive position, and success or failure of our
products or product candidates.Further, the discovery of significant problems
with a product similar to one of our products that implicate an entire class
of products could have a material adverse effect on sales of the affected
products and on our business and results of operations.

The scientific information discussed in this news release related to our
product candidates is preliminary and investigative.Such product candidates
are not approved by theU.S. Food and Drug Administration (FDA), and no
conclusions can or should be drawn regarding the safety or effectiveness of
the product candidates.

Kristen Davis, 805-447-3008 (media)
Arvind Sood, 805-447-1060 (investors)


^1 National Cancer Institute, National Institute of Health, Dept. of Health
and Human Services; What You Need to Know About Melanoma and Other Skin
Cancers; June 2010.
^2 American Cancer Society. Surgery for Metastatic Skin Cancer.
Accessed August 28, 2013.^
^3 American Cancer Society. What is Metastatic Skin Cancer.
Accessed August 28, 2013.^
^4 Lin AY, et al. Melanoma Res. 2012; 22:454-459
^5 Ultraviolet radiation and the INTERSUN Programme. World Health
Organization. Accessed
May 13, 2013.^


Press spacebar to pause and continue. Press esc to stop.